Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic and clinical characteristics of the juvenile idiopathic arthritis patients from different registries

From: Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries

  Pharmachild
N = 8274
BiKeR
N = 3990
Sweden
N = 3020
Number of countries 32 2# 1
Number of centers 86 72 33
Number of patients per center 55.5 (17–124) 10.5 (3–39.8) 52 (31–78)
Age at onset 5.4 (2.4–10.0) 7.6 (3.2–11.7) 7.6 (2.9–11.7)1
Age at JIA diagnosis 6.2 (2.8–10.9) 8.3 (3.5–12.8)2
Disease duration at last visit 5.3 (2.7–8.8) 6.1 (3.5–9.5) 6.8 (4.3–10.1)3
Female 5584 (67.5%) 2670 (66.9%) 1989 (65.9%)
Antinuclear antibodies (ANA)* 1767 (21.4%) 1900 (47.6%)
ILAR JIA category   4 5
 Systemic 911 (11.0%) 267 (6.7%) 109 (4.7%)
 Oligo 3071 (37.1%) 1215 (30.5%) 1148 (49.6%)
  Oligo persistent 2011 (24.3%) 494 (12.4%)
  Oligo extended 1060 (12.8%) 721 (18.1%)
 Polyarticular RF 2183 (26.4%) 1192 (29.9%) 568 (24.6%)
 Polyarticular RF+ 322 (3.9%) 243 (6.1%) 85 (3.7%)
 Psoriatic arthritis 285 (3.4%) 296 (7.4%) 160 (6.9%)
 Enthesitis-related arthritis 924 (11.2%) 649 (16.3%) 185 (8.0%)
 Undifferentiated arthritis 578 (7.0%) 127 (3.2%) 58 (2.5%)
  1. Data are medians (1st–3rd quartiles) or frequencies (percentages)
  2. *ANA at least two consecutively positive determinations according to local standards
  3. # Germany and Austria
  4. 1data available for 2477 subjects
  5. 2data available for 2197 subjects
  6. 3data available for 2479 subjects
  7. 4data available for 3989 subjects
  8. 5data available for 2313 subjects
  9. Abbreviations: BiKeR Biologics in Pediatric Rheumatology Registry, ILAR International League of Associations for Rheumatology, JIA juvenile idiopathic arthritis, RF rheumatoid factor